Osanni Bio operates an innovation engine optimized for discovering scientific insights, designing novel drug concepts, and efficiently advancing programs to meaningful proof-of-concept. The platform-centric architecture combines centralized scientific and operational resources with an ecosystem of affiliate companies that receive graduated, de-risked programs and dedicated teams to scale them. Osanni is advancing multiple programs in ophthalmology and cardiology, among other areas. The company is headquartered in San Francisco and is led by a team of inventors and entrepreneurs with repeat company-creation experience. Financially, Osanni just closed a $190 million Series B led by Patient Square Capital to advance its pipeline and scale its discovery and development process.

Total raised

$217M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2026